Our MISSION, is to serve the community of Interventional Cardiologists to diagnose and treat myocardial infarction being among the n° 1 killers in the world to save the lives of patients and to better improve their quality of life. To accomplish this goal Hexacath mission is based on innovation and close partnership with Key Opinion Leaders in Cardiology.  

Myocardial infarction was usually known as acute events mainly caused by a blockage preventing blood from flowing to the heart and in this case the most common reason for this is a build-up of fatty deposits on the inner walls of the blood vessels that supply the heart.

Hexacath has targeted this disease developing a unique coronary stent TiTAN OPTIMAX based on a bioactive coating material known as titanium nitride oxide able to reduce both thrombosis and restenosis capable to promote healing post stenting and reducing therefore the need for prolonged Dual Anti Platelet Treament (1, 2, 3, 4, 5, 6, 7, 8, 9).

In addition, physicians have also discovered that up to 50% of patients with chest pain visiting catheterization laboratories do not present with significant epicardial stenosis meaning this dreadful pathology is caused by something else beyond coronary arteries known as the interventional cardiology “Black Box” or Coronary Microcirculation Dysfunction (10, 11).

It took nearly 10 years to Hexacath to develop and patent the RayFlow microcatheter the Key to understand and treat coronary microcirculation dysfunction known as ANOCA (Angina with non obstructive Coronary Arteries) or MINOCA (Myocardial Infarction with Non Obstructive Coronary Arteries).